Claudin18.2 Targeted CAR-T Cells

Phase 1Cell therapy

SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Claudin18.2 Targeted CAR-T Cells is one of 67 biologic programs targeting Colorectal Cancer. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Colorectal CancerActive, not recruiting

Pancreatic CancerActive, not recruiting

Colorectal CancerPhase 1

Active, not recruiting

Pancreatic CancerPhase 1

Active, not recruiting

Competition

Competitive Landscape

1063 competitors in Pancreatic Cancer

#DrugCompanyPhaseTrials

Gemzar

GGynecologic Oncology Group

Byetta

1 3

ABI-007

Bristol-Myers Squibb

Preclinical

2 4

LDE225

Novartis

Preclinical

1 5

Sulfonylureas

Eli Lilly

Preclinical

1 6

Thiazolidinediones

Sanofi

Preclinical

1 7

Alpha-Glucosidase Inhibitors

Sanofi

Preclinical

1 8

Meglitinides

Sanofi

Preclinical

1 9

Secretin-Ferring

Ferring

Preclinical

1 10

Concurrent Lenvatinib

TTrans Tasman Radiation Oncology Group

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

Phase 1Recruiting

Colorectal Cancer

NCT06946615

Q3 2028

Phase 1Recruiting

Pancreatic Cancer

NCT07416240

Clinical

Trials by Indication[1]

Colorectal Cancer1 trial

Exploratory Clinical Study of Claudin18.2-Targeted CAR-DC and CAR-T Therapy in Advanced Colorectal Cancer

Recruiting·SSecond Affiliated Hospital, School of Medicine, Zhejiang University·Phase 1·NCT06946615·18 enrolled

Pancreatic Cancer1 trial

Exploratory Clinical Study of Claudin18.2-Targeted Activated DC and CAR-T Therapy in Advanced Pancreatic Cancer.

Recruiting·HHainan Cancer Hospital·Phase 1·NCT07416240·10 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Claudin18.2 Targeted CAR-T Cells. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Claudin18.2 Targeted CAR-T Cells compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Claudin18.2 Targeted CAR-T Cells. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Second Affiliated Hospital, School of Medicine, Zhejiang University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Cell therapy[2]
Highest Phase: Phase 1[1]
Company: SSecond Affiliated Hospital, School of Medicine, Zhejiang University

Claudin18.2 Targeted CAR-T Cells

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Q3 2028

Trials by Indication[1]

Colorectal Cancer1 trial

Pancreatic Cancer1 trial

References

Drug Info

Quick Facts

Related News